Mallinckrodt Scientists On Capitol Hill to Advocate for Biopharmaceutical Innovation

The science of hope. The promise of innovation. This was the message heard throughout Capitol Hill during the Pharmaceutical Research and Manufacturers of America’s (PhRMA) first congressional “fly-in” focused specifically on the merits of drug discovery and development. More than 60 researchers and scientists from some of the top pharmaceutical companies in the world – including Mallinckrodt – were there to help shine a light on the extraordinary work that’s taking place in the biopharmaceutical industry every day.

Over 170 meetings were conducted with members of Congress and their senior staff to discuss the incredible progress that’s been made in the fight against serious diseases, as well as emphasize the important role Congress plays in supporting policies facilitating the development of new, innovative medicines for patients in need. Mallinckrodt’s own, Claire Brook, Principal Analytical Chemist, and Baohua Yue, Senior Principal Formulation Scientist, both based in St. Louis, Missouri, participated in the meetings.

“The fly-in was a great opportunity to tell legislators about the exciting research we are working on at Mallinckrodt,” said Baohua. “We had meaningful dialogues with the legislators about the challenges threatening innovation in our industry, and the need for policies that continues to foster research and development.”

Claire and Baohua met directly with several members of the Missouri congressional delegation educating them on topics including, Mallinckrodt’s extensive preclinical and clinical studies that are performed for new drugs, our cutting edge research in rare diseases, the new regenerative medicine in development, our autoimmune and hospital products, as well as our abuse-deterrent product development program and other initiatives to help prevent opioid drug abuse and diversion.

“The PhRMA fly-in was an important step towards educating our policymakers on Mallinckrodt’s and our industry’s innovative activities,” said Erika Long, Senior Director, Federal Affairs. “Both Bao and Claire made a very positive impression on the congressional offices they visited. We can’t thank them enough for their enthusiasm and engagement.”

To learn more about the work America’s biopharmaceutical research companies are doing to advance science, visit:


From left: Claire Brook, Principal Analytical Chemist; Congresswoman Ann Wagner; Baohua Yue, Senior Principal Formulation Scientist; Erika Long, Senior Director, Federal Affairs.


From left: Baohua Yue, Senior Principal Formulation Scientist; Congressman Jason Smith; Claire Brook, Principal Analytical Chemist.